Rapid COVID-19 Test May Miss Large Number Of Cases

The Abbott ID test, approved by the FDA for rapid COVID-19 results, was found to miss nearly half of positive cases in a preliminary NYU study. The study, not yet peer-reviewed, deemed the test's accuracy unacceptable. Abbott questioned the study's methodology, claiming a false negative rate of 0.02% and defending the test's performance. The test is widely distributed and used by the White House, which has not commented on the study.

What is the primary purpose of the Abbott ID test?

• To be used exclusively in hospitals

• To replace all other COVID-19 tests

• To test for all types of viruses

• To provide rapid COVID-19 results

What was a major concern raised by the New York University study about the Abbott ID test?

• It was too expensive

• It missed nearly half of the positive cases

• It took too long to deliver results

• It was not approved by the FDA

How did Abbott respond to the study's findings?

• By recalling the tests

• By questioning the study's methodology

• By stopping the distribution of tests

• By admitting the test's flaws

What is the claimed false negative rate of the Abbott ID test according to the company?

• 10%

• 0.02%

• 5%

• 1%

How has the White House utilized the Abbott ID test?

• For testing only symptomatic individuals

• For research purposes

• For screening its staff

• For public testing